0 479

Cited 43 times in

Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy

DC Field Value Language
dc.contributor.author성진실-
dc.contributor.author장지석-
dc.contributor.author정승연-
dc.date.accessioned2018-07-20T07:34:00Z-
dc.date.available2018-07-20T07:34:00Z-
dc.date.issued2017-
dc.identifier.issn0167-8140-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/160294-
dc.description.abstractPURPOSE: To investigate whether radiotherapy (RT) dose escalation would improve treatment outcomes without increasing severe toxicity in locally advanced pancreatic cancer patients. METHODS: From 2005 to 2015, 497 locally advanced pancreatic cancer patients who received neoadjuvant or definitive chemoradiotherapy (CCRT) were included. Patients were divided according to the total dose (TD). Overall survival (OS), progression-free survival (PFS), local failure-free rate (LFFR), distant failure-free rate (DFFR), and toxicity rates were compared between <61Gy (n=345) and ≥61Gy groups (n=152). Additionally, propensity score matching was performed. RESULTS: At a median follow-up of 19.3months (range, 4.8-128.5months), the 1-year OS, PFS, LFFR, and DFFR were significantly higher in the ≥61Gy group. After multivariate analysis, a TD of ≥61Gy remained a significant favorable factor for OS (p=0.019), PFS (p=0.001), LFFR (p=0.004), and DFFR (p=0.008). After propensity score matching, the ≥61Gy group still showed higher OS, PFS, and LFFR, but not DFFR (p=0.205). The acute and late toxicity rates showed no significant difference between the two groups. CONCLUSION: Patients who received a higher RT dose showed not only improved PFS and LFFR, but also improved OS without an increase in severe toxicity. Dose-escalated CCRT can be a favorable treatment option in locally advanced pancreatic cancer patients.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier Scientific Publishers-
dc.relation.isPartOfRADIOTHERAPY AND ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHChemoradiotherapy*-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoadjuvant Therapy-
dc.subject.MESHPancreatic Neoplasms/mortality-
dc.subject.MESHPancreatic Neoplasms/therapy*-
dc.subject.MESHRadiotherapy Dosage-
dc.subject.MESHRetrospective Studies-
dc.titleDose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Radiation Oncology-
dc.contributor.googleauthorSeung Yeun Chung-
dc.contributor.googleauthorJee Suk Chang-
dc.contributor.googleauthorByung Min Lee-
dc.contributor.googleauthorKyung Hwan Kim-
dc.contributor.googleauthorKyong Joo Lee-
dc.contributor.googleauthorJinsil Seong-
dc.identifier.doi10.1016/j.radonc.2017.04.010-
dc.contributor.localIdA01956-
dc.contributor.localIdA04658-
dc.contributor.localIdA05411-
dc.relation.journalcodeJ02597-
dc.identifier.eissn1879-0887-
dc.identifier.pmid28464997-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0167814017301512-
dc.subject.keywordChemoradiotherapy-
dc.subject.keywordDose escalation-
dc.subject.keywordPancreatic cancer-
dc.contributor.alternativeNameSeong, Jin Sil-
dc.contributor.alternativeNameChang, Jee Suk Paul-
dc.contributor.alternativeNameChung, Seung Yeun-
dc.contributor.affiliatedAuthorSeong, Jin Sil-
dc.contributor.affiliatedAuthorChang, Jee Suk Paul-
dc.contributor.affiliatedAuthorChung, Seung Yeun-
dc.citation.volume123-
dc.citation.number3-
dc.citation.startPage438-
dc.citation.endPage445-
dc.identifier.bibliographicCitationRADIOTHERAPY AND ONCOLOGY, Vol.123(3) : 438-445, 2017-
dc.identifier.rimsid40403-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.